Research information only, not medical advice. In clinical trials, retatrutide produced large reductions in body weight — about 24% at 48 weeks in a phase 2 obesity trial — and improved blood-sugar control in type 2 diabetes. It remains investigational and is not approved for any use.
The main outcomes studied for retatrutide are weight loss and glycemic control. In a phase 2 obesity trial, retatrutide 12 mg produced a mean body-weight reduction of about 24% at 48 weeks (Jastreboff et al., NEJM 2023); the manufacturer has reported about 28% at 80 weeks in the phase 3 TRIUMPH-1 trial, a figure from an Eli Lilly news release that is not yet peer-reviewed. In a separate 40-week phase 3 trial in adults with type 2 diabetes, retatrutide lowered HbA1c by roughly 1.7 to 1.9 percentage points and reduced body weight by up to about 15% versus placebo (Bajaj et al.). These are trial results for an investigational drug, reported here as evidence rather than as medical advice.
For the full evidence base, clinical trials, and regulatory status, see the Retatrutide research overview . Related: retatrutide side effects , retatrutide dosage .
Sources
Frequently asked questions
- How much weight did retatrutide cause in trials?
- A phase 2 obesity trial reported about 24% mean body-weight reduction at 48 weeks with retatrutide 12 mg; the manufacturer has reported about 28% at 80 weeks in the phase 3 TRIUMPH-1 trial (an Eli Lilly release, not yet peer-reviewed).
- Does retatrutide help type 2 diabetes?
- In a phase 3 trial in adults with type 2 diabetes, retatrutide lowered HbA1c by roughly 1.7 to 1.9 percentage points versus placebo alongside weight loss. Retatrutide remains investigational.
Updated · sourced to primary documents